Life Science Investing NRx Pharmaceuticals, Inc. to Present at Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference
Life Science Investing NRx Pharmaceuticals, Inc. Re-Files Abbreviated New Drug Application for KETAFREE, Preservative-Free IV Ketamine
Life Science Investing NRx Pharmaceuticals, Inc. Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx's Proposed Strength of Preservative-Free Ketamine
Life Science Investing HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. Complete the Acquisition of Dura Medical; Initial Acquisition in Network of Interventional Psychiatry Clinics
Life Science Investing NRx Pharmaceuticals to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
LaFleur Minerals Provides Update on PEA for the Restart of Beacon Gold Mill Sourcing Material from Its Swanson Gold Deposit, Val d'Or, Québec
